Bank of New York Mellon Corp decreased its stake in shares of Livongo Health (NASDAQ:LVGO) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 172,301 shares of the company’s stock after selling 4,923 shares during the quarter. Bank of New York Mellon Corp owned about 0.18% of Livongo Health worth $12,955,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in LVGO. BlackRock Inc. grew its position in shares of Livongo Health by 181.1% during the 1st quarter. BlackRock Inc. now owns 3,598,006 shares of the company’s stock worth $102,652,000 after buying an additional 2,318,002 shares during the period. Matrix Capital Management Company LP acquired a new stake in Livongo Health in the 1st quarter valued at $21,909,000. Ashford Capital Management Inc. acquired a new stake in Livongo Health in the 1st quarter valued at $21,276,000. State Street Corp grew its position in Livongo Health by 257.6% in the 1st quarter. State Street Corp now owns 927,891 shares of the company’s stock valued at $26,473,000 after purchasing an additional 668,404 shares during the period. Finally, Ardevora Asset Management LLP acquired a new stake in Livongo Health in the 2nd quarter valued at $48,254,000. 41.67% of the stock is owned by institutional investors.

Several research firms recently issued reports on LVGO. Goldman Sachs Group downgraded shares of Livongo Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $48.00 to $70.00 in a research report on Thursday, July 2nd. SVB Leerink raised their price objective on Livongo Health from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Friday, June 12th. Citigroup raised their price objective on Livongo Health from $125.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Canaccord Genuity raised their price objective on Livongo Health from $110.00 to $139.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Finally, Stifel Nicolaus cut Livongo Health from a “buy” rating to a “hold” rating and set a $137.00 price objective on the stock. in a research note on Monday, August 24th. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Livongo Health presently has an average rating of “Buy” and an average price target of $90.11.

In other Livongo Health news, insider James Pursley sold 738 shares of Livongo Health stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $132.53, for a total value of $97,807.14. Following the completion of the sale, the insider now owns 73,294 shares of the company’s stock, valued at approximately $9,713,653.82. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Zane M. Burke sold 49,115 shares of Livongo Health stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $124.50, for a total value of $6,114,817.50. Following the completion of the sale, the chief executive officer now directly owns 964,838 shares of the company’s stock, valued at approximately $120,122,331. The disclosure for this sale can be found here. Insiders sold a total of 778,716 shares of company stock worth $94,553,803 in the last 90 days. 13.00% of the stock is currently owned by company insiders.

Shares of NASDAQ:LVGO opened at $124.43 on Wednesday. The stock has a market cap of $12.48 billion, a PE ratio of -303.48 and a beta of 1.75. The company’s fifty day moving average is $127.91 and its 200 day moving average is $72.46. Livongo Health has a 52 week low of $15.12 and a 52 week high of $150.00. The company has a quick ratio of 19.51, a current ratio of 19.88 and a debt-to-equity ratio of 0.69.

Livongo Health (NASDAQ:LVGO) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.17. The firm had revenue of $91.90 million for the quarter, compared to analysts’ expectations of $86.68 million. Livongo Health had a negative net margin of 12.76% and a negative return on equity of 4.86%. The company’s revenue for the quarter was up 124.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.46) earnings per share.

About Livongo Health

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

Featured Article: Trading signals using Bollinger bands

Want to see what other hedge funds are holding LVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Livongo Health (NASDAQ:LVGO).

Institutional Ownership by Quarter for Livongo Health (NASDAQ:LVGO)

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.